• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PSMA-PET in Canada: More questions than answers.

作者信息

Morris Heather, Lavallée Luke T

机构信息

Division of Urology, The University of Ottawa, Ottawa, ON, Canada.

出版信息

Can Urol Assoc J. 2023 Aug;17(8):254. doi: 10.5489/cuaj.8490.

DOI:10.5489/cuaj.8490
PMID:37581547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10426419/
Abstract
摘要

相似文献

1
PSMA-PET in Canada: More questions than answers.加拿大的前列腺特异性膜抗原正电子发射断层扫描：问题多于答案。
Can Urol Assoc J. 2023 Aug;17(8):254. doi: 10.5489/cuaj.8490.
2
Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada.建立省级复发性前列腺癌登记处：在加拿大安大略省提供PSMA PET/CT检查服务。
Front Oncol. 2021 Aug 2;11:722430. doi: 10.3389/fonc.2021.722430. eCollection 2021.
3
A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies.原发性分期研究中前列腺内前列腺特异性膜抗原正电子发射断层扫描操作与报告变异性的系统评价
Eur Urol Open Sci. 2023 Mar 3;50:91-105. doi: 10.1016/j.euros.2023.01.010. eCollection 2023 Apr.
4
The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review.PSMA PET/CT在前列腺癌初诊及随访中的作用——一项实用临床综述
Cancers (Basel). 2022 Jul 26;14(15):3638. doi: 10.3390/cancers14153638.
5
PET/CT With Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.前列腺癌中使用镓-前列腺特异性膜抗原的正电子发射断层扫描/计算机断层扫描：放射性药物背景及临床意义
Curr Radiopharm. 2018;11(1):4-13. doi: 10.2174/1874471010666171101121803.
6
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.PSMA PET/CT 引导下高危前列腺癌患者的强化治疗（PATRON）：一项实用的 III 期随机对照试验。
BMC Cancer. 2022 Mar 8;22(1):251. doi: 10.1186/s12885-022-09283-z.
7
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
8
Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with Ra: Proof of Concept.镓-PSMA-11正电子发射断层扫描作为镭治疗转移性前列腺癌的把关者：概念验证
J Nucl Med. 2017 Mar;58(3):438-444. doi: 10.2967/jnumed.116.178533. Epub 2016 Sep 22.
9
Case Report: F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer.病例报告：F-PSMA PET/CT 可能改善前列腺癌阴茎转移的临床管理。
Front Oncol. 2021 May 13;11:683343. doi: 10.3389/fonc.2021.683343. eCollection 2021.
10
Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.PSMA PET 成像中的非前列腺疾病：一系列良性和恶性表现。
Cancer Imaging. 2020 Mar 14;20(1):23. doi: 10.1186/s40644-020-00300-7.

引用本文的文献

1
Engaging for equity: Lessons from a cross-sector partnership addressing prostate cancer risk in the black community.追求公平：跨部门合作应对黑人社区前列腺癌风险的经验教训。
Res Involv Engagem. 2025 Jun 10;11(1):60. doi: 10.1186/s40900-025-00743-x.

本文引用的文献

1
F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study.F-DCFPyL PSMA-PET对前列腺切除术后生化复发患者挽救性放疗管理的影响：一项配对队列研究。
Can Urol Assoc J. 2023 Aug;17(8):247-253. doi: 10.5489/cuaj.8165.
2
The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.PSMA PET 对前列腺癌生化复发患者治疗和结局的影响：系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2023 Jun;26(2):240-248. doi: 10.1038/s41391-022-00544-3. Epub 2022 Apr 19.
3
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.PSMA PET/CT 引导下高危前列腺癌患者的强化治疗（PATRON）：一项实用的 III 期随机对照试验。
BMC Cancer. 2022 Mar 8;22(1):251. doi: 10.1186/s12885-022-09283-z.
4
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
5
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.针对分子定义寡转移前列腺癌的治愈意向转移定向治疗：一项测试寡转移假说的前瞻性 II 期试验。
Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6.
6
3-Year Freedom from Progression After Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial.根治性前列腺切除术后生化复发男性患者经 Ga-PSMA PET/CT 分诊管理后 3 年无进展：一项前瞻性多中心试验的结果。
J Nucl Med. 2020 Jun;61(6):866-872. doi: 10.2967/jnumed.119.235028. Epub 2019 Nov 1.
7
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.68Ga-PSMA-11 PET 定位复发性前列腺癌的准确性评估：一项前瞻性单臂临床试验。
JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.